Gene therapy biopharma uniQure files for a $75 million IPO

By Renaissance Capital,

Shutterstock photo

uniQure, which develops gene therapies for the treatment of orphan diseases, filed on Thursday with the SEC to raise up to $75 million in an initial public offering. The Amsterdam, Netherlands-based company, which was founded in 1998 and booked $3 million in licensing and collaboration revenue for the 12 months ended September 30, 2013, plans to list on the NASDAQ under the symbol QURE. Jefferies, Leerink Swann and Piper Jaffray are the joint bookrunners on the deal. No pricing terms were disclosed.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.

This article appears in: News Headlines IPOs
Referenced Stocks: QURE

More from Renaissance Capital


Renaissance Capital

Renaissance Capital

Follow on:

Find a Credit Card

Select a credit card product by:
Select an offer:
Data Provided by